Evaluating the US pharmaceutical patent policy / Olena Izhak, Tanja Saxell and Tuomas Takalo
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect of patent length and scope on generic entry prior to the expiration of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the allocation of patent applications to examiners. We find that extending effective patent length increases generic entry whereas broadening protection reduces it. To assess the welfare effects of patent policy, we match these empirical results with a model of new drug development, generic entry, and patent length and scope. Optimal policy calls for shorter but broader pharmaceutical patents..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
29 December 2021 |
|---|---|
| Erschienen: |
Helsinki: Bank of Finland ; 29 December 2021 |
| Reihe: |
Bank of Finland research discussion papers - 2021, 16 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Izhak, Olena [VerfasserIn] |
|---|
| Links: |
helda.helsinki.fi [kostenfrei] |
|---|
| ISBN: |
|---|
| Themen: |
Generic entry |
|---|
| Umfang: |
1 Online-Ressource (circa 67 Seiten) ; Illustrationen |
|---|
| Weitere IDs: |
urn:nbn:fi:bof-202112302177 10419/249596 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1787071340 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1787071340 | ||
| 003 | DE-627 | ||
| 005 | 20230911124908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220125s2021 fi |||||o 00| ||eng c | ||
| 020 | |a 9789523233942 |9 978-952-323-394-2 | ||
| 024 | 7 | |a urn:nbn:fi:bof-202112302177 |2 urn | |
| 024 | 7 | |a 10419/249596 |2 hdl | |
| 035 | |a (DE-627)1787071340 | ||
| 035 | |a (DE-599)KXP1787071340 | ||
| 035 | |a (OCoLC)1392168836 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-FI | ||
| 084 | |a I18 |a K20 |a L13 |a O34 |a O31 |2 jelc | ||
| 100 | 1 | |a Izhak, Olena |e verfasserin |0 (DE-588)1176741500 |0 (DE-627)1047765616 |0 (DE-576)51678675X |4 aut | |
| 245 | 1 | 0 | |a Evaluating the US pharmaceutical patent policy |c Olena Izhak, Tanja Saxell and Tuomas Takalo |
| 264 | 1 | |a Helsinki |b Bank of Finland |c 29 December 2021 | |
| 300 | |a 1 Online-Ressource (circa 67 Seiten) |b Illustrationen | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Bank of Finland research discussion papers |v 2021, 16 | |
| 520 | |a The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect of patent length and scope on generic entry prior to the expiration of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the allocation of patent applications to examiners. We find that extending effective patent length increases generic entry whereas broadening protection reduces it. To assess the welfare effects of patent policy, we match these empirical results with a model of new drug development, generic entry, and patent length and scope. Optimal policy calls for shorter but broader pharmaceutical patents. | ||
| 650 | 4 | |a Patent policy |7 (dpeaa)DE-206 | |
| 650 | 4 | |a pharmaceuticals |7 (dpeaa)DE-206 | |
| 650 | 4 | |a generic entry |7 (dpeaa)DE-206 | |
| 650 | 4 | |a innovation |7 (dpeaa)DE-206 | |
| 650 | 4 | |a imitation |7 (dpeaa)DE-206 | |
| 700 | 1 | |a Saxell, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Takalo, Tuomas |e verfasserin |0 (DE-588)171526864 |0 (DE-627)061736902 |0 (DE-576)132314371 |4 aut | |
| 810 | 2 | |a Suomen Pankki |t Bank of Finland research discussion papers |v 2021, 16 |9 2021,16 |w (DE-627)512198756 |w (DE-576)28130985X |w (DE-600)2236524-2 |x 1456-6184 |7 ns | |
| 856 | 4 | 0 | |u https://helda.helsinki.fi/bof/bitstream/handle/123456789/18258/BoF_DP_2116.pdf?sequence=1&isAllowed=y |x Verlag |z kostenfrei |
| 856 | 4 | 0 | |u http://nbn-resolving.de/URN:NBN:fi:bof-202112302177 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u http://hdl.handle.net/10419/249596 |x Resolving-System |z kostenfrei |
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a ISIL_DE-206 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 951 | |a BO | ||
| 980 | |2 20 |1 01 |x 0084 |b 4363187565 |y z |z 04-08-23 | ||
| 980 | |2 26 |1 01 |x 0206 |b 4043403410 |c 08 |f K: |d DS 685 |e --%%-- |j --%%-- |y z1k |z 25-01-22 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4053278465 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 08-02-22 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://helda.helsinki.fi/bof/bitstream/handle/123456789/18258/BoF_DP_2116.pdf?sequence=1&isAllowed=y | ||